Skip to main content
Full access
Letters
Published Online: 1 April 2012

Zolpidem Misuse in Two Women With No Psychiatric History: A Crucial Role of Pleasant Visual Hallucinations

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Although zolpidem is thought to be a safer drug than benzodiazepines, its abuse potential is not as low as previously reported. Zolpidem is abused for its sedative-hypnotic properties1 or for psychomotor activation and euphoria.2 We describe two women who used zolpidem for months because of pleasant visual hallucinations experienced after low doses of the drug.

Case Report

Two unrelated women (“Mrs. A,” age 21, and “Mrs. B,” age 28) had self-referred to a psychiatrist because of zolpidem misuse (10 mg–15 mg per dose, 1–2 times per week) associated with pleasant visual hallucinations. Both Mrs. A and Mrs. B had no personal or family history of psychiatric disorders and did not take any other medications. The subjects were nonsmokers, and occasionally used alcohol and cannabis, but not other drugs of abuse. Neither Mrs. A nor Mrs. B reported any visual abnormalities requiring ophthalmological treatment.
Both women started zolpidem use for sleep-onset insomnia after receiving the drug from a family member. Approximately 30 minutes after the first and successive zolpidem administrations, the subjects experienced florid visual hallucinations lasting 20–30 minutes, and associated with relaxation but not drowsiness. They saw, for example, dwarfs sitting by a fireplace, dancing mascots, a tongue-shaped robot, and ghosts flying around a TV set. Mrs. B often potentiated her sensations by playing video games. Diplopia was experienced by both subjects, and mild agitation with logorrhea was occasionally experienced by the older woman. The subjects were aware that the things they saw were unreal. Neither Mrs. A nor Mrs. B developed zolpidem dependence.

Comment

To the best of our knowledge, this is the first report of zolpidem misuse associated with pleasant visual (pseudo)hallucinations induced by low doses of the drug in otherwise healthy subjects. Zolpidem-induced hallucinations described in previous reports were experienced by subjects with psychiatric disorders,1,2 taking psychotropic medications,3 suffering from severe visual impairment,4 taking large doses of zolpidem,1,2 or passively exposed to zolpidem in a clinical trial.5
It remains to be established whether pleasant hallucinations may lead to zolpidem addiction. It should also be clarified whether zolpidem-induced hallucinations are primarily associated with disturbances in psychosis-related limbic brain areas and/or with alterations in GABA signaling in the visual cortex.4

Acknowledgments

Preparation of the present report was supported by the Ministry of Science and Graduate Education, Warsaw, Poland (grant no. 5887/B/P01/2011/40 to P.M.).

References

1.
Sakkas P, Psarros C, Masdrakis V, et al.: Dependence on zolpidem: a case report. Eur Psychiatry 1999; 14:358–359 doi:10.1016/S0924-9338(99)00152-2
2.
Victorri-Vigneau C, Dailly E, Veyrac G, et al.: Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007; 64:198–209 doi:10.1111/j.1365-2125.2007.02861.x
3.
Elko CJ, Burgess JL, Robertson WO: Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 1998; 36:195–203
4.
Stofler PM, Franzooni S, Di Fazio I, et al.: Charles Bonnet syndrome and GABAergic drugs: a case report. J Am Geriatr Soc 2004; 52:646–647
5.
de Haas S, Dingemanse J, Hoever P, et al.: Pseudohallucinations after zolpidem intake: a case report. J Clin Psychopharmacol 2007; 27:728–730

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E32
PubMed: 22772691

History

Published online: 1 April 2012
Published in print: Spring 2012

Authors

Details

Lukasz Kummer, M.D.
Institute of Psychiatry and Neurology, Warsaw
Malgorzata Rzewuska, M.D., Ph.D.
Institute of Psychiatry and Neurology, Warsaw
Halina Sienkiewicz-Jarosz, M.D., Ph.D.
Institute of Psychiatry and Neurology, Warsaw
Pawel Mierzejewski, M.D., Ph.D.
Institute of Psychiatry and Neurology, Warsaw
Przemyslaw Bienkowski, M.D., Ph.D.
Institute of Psychiatry and Neurology, Warsaw
Jerzy Samochowiec, M.D., Ph.D.
Department of Psychiatry, Pomeranian Medical University, Szczecin, Poland

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share